Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.

BMC neuroscience - 10 May 2004

Gil Joana M A C, Leist Marcel, Popovic Natalija, Brundin Patrik, Petersén Asa

Abstract excerpt

BACKGROUND: Huntington's disease (HD) is a hereditary neurodegenerative disorder caused by an expanded CAG repeat in the HD gene. Both excitotoxicity and oxidative stress have been proposed to play important roles in the pathogenesis of HD. Since no effective treatment is available, this study was designed to explore the therapeutic potential of erythropoietin (EPO), a cytokine that has been found to prevent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Behavior, Animal
Share to Cytokines
Share to Dentate Gyrus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erythropoietin

Share to Huntington Disease

Share to Neuroprotective Agents

Share to Treatment Failure

Share to Weight Loss

Source

Open in PubMed Open full text

Identifiers

PMID: 15134587
DOI: 10.1186/1471-2202-5-17
PMCID: PMC434499

Genes

EPO

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice.PMID 15134587Read ↗

Lentiviral delivery of human erythropoietin attenuates hippocampal atrophy and improves cognition in the R6/2 mouse model of Huntington's diseaseSemantic proximity Read ↗

Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity <i>in vivo</i>Semantic proximity Read ↗

Intervention of Proliferation and Differentiation of Endogenous Neural Stem Cells in the Neurodegenerative Process of Huntington's Disease Phenotype.Semantic proximity Read ↗

Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease miceSemantic proximity Read ↗

Impaired adult olfactory bulb neurogenesis in the R6/2 mouse model of Huntington's disease.Semantic proximity Read ↗

Recombinant human erythropoietin reduces aggregation of mutant Cu/Zn-binding superoxide dismutase (SOD1) in NSC-34 cells.Semantic proximity Read ↗

Striatal infusion of glial conditioned medium diminishes huntingtin pathology in r6/1 mice.Semantic proximity Read ↗

Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.Semantic proximity Read ↗

CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.Semantic proximity Read ↗

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.Semantic proximity Read ↗

Widespread Expression of Erythropoietin Receptor in Brain and Its Induction by InjurySemantic proximity Read ↗

Non-erythropoietic erythropoietin derivatives protect from light-induced and genetic photoreceptor degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.